Juvenile myoclonic epilepsy, valproate and a planned pregnancy

Frame the trade-off explicitly. Valproate is the most effective single drug for juvenile myoclonic epilepsy and her myoclonus is currently controlled, so switching carries a genuine risk of breakthrough jerks and generalised seizures. Against that, valproate is the most teratogenic antiseizure medication: major congenital malformations in roughly 10% of exposed pregnancies and neurodevelopmental disorders in a substantial minority, with risk rising with dose. At 1000 mg/day she is in a higher-risk dose band. Because JME is lifelong, this decision has to be planned over months, not weeks - the earlier failed 3-week switch was too fast and set her against change.

Plan:

1. Do not stop valproate abruptly; she is seizure-free and abrupt withdrawal risks status.
2. Choose levetiracetam or lamotrigine. Levetiracetam is easier to titrate and has no pharmacokinetic interaction; lamotrigine is well established in pregnancy but must be built up slowly and its clearance changes dramatically in pregnancy. Many epilepsy services would use levetiracetam first here because of the previous lamotrigine failure.
3. Overlap: introduce and titrate the new drug to a therapeutic dose over 6–8 weeks before beginning to reduce valproate, by 250 mg every 2–4 weeks.
4. Anticipate the interaction: valproate inhibits lamotrigine metabolism. If lamotrigine is chosen, doses must be increased as valproate is withdrawn or levels will fall and myoclonus will recur.
5. Reinforce sleep regularity, alcohol avoidance and adherence; give a written rescue plan.
6. If she cannot tolerate any switch, use the lowest effective valproate dose (aim <600 mg/day, slow-release, divided) with documented counselling - but only after a genuine attempt.

Contraception: taking valproate plus topiramate with no contraception is the most urgent problem. She needs a reliable method before any switch is attempted. Offer a long-acting reversible contraceptive - copper IUD or levonorgestrel IUS - because topiramate can induce enzymes and reduce combined oral contraceptive reliability, and because adherence with pills is fragile during a drug switch. Document a pregnancy-prevention discussion.

Topiramate: stop or replace it. It roughly doubles the risk of oral clefts, is associated with small-for-gestational-age infants, and can cause cognitive slowing and kidney stones. For migraine with aura she needs an alternative prophylactic: propranolol or amitriptyline are both acceptable in pregnancy and breastfeeding. For acute attacks, paracetamol and, if needed, sumatriptan are generally considered acceptable; avoid ergots.

Pre-conception:

• Folic acid 5 mg daily for at least 3 months before conception.
• Baseline full blood count, liver function, vitamin D and weight; counsel about valproate-related weight gain and polycystic ovarian features.
• Treat her BMI and sleep pattern as seizure triggers.
• Arrange joint epilepsy–obstetric care and pre-pregnancy counselling with a written plan.
• Explain that the aim is a stable, lowest-risk regimen before conception, not a rushed switch in early pregnancy.

Do not stop valproate abruptly - withdrawal risks generalised seizures and status epilepticus, which endanger both mother and fetus.

Immediate steps:

1. Urgent joint review with obstetric/teratology services; same-week appointment, not routine.
2. Start folic acid 5 mg immediately (late, but still worthwhile) and stop topiramate now, replacing the migraine prophylaxis with propranolol.
3. Consider reducing valproate to the lowest effective dose, in divided slow-release form, with monitoring - but change only with a clear plan and follow-up, and never as an emergency taper.
4. Detailed counselling on malformation and neurodevelopmental risk, non-directive and documented; offer support whatever she decides.
5. Monitoring: anomaly scan at 11–13⁺⁶ weeks and a detailed scan plus fetal echocardiography at 18–22 weeks.
6. Drug levels: valproate levels fall in pregnancy; lamotrigine and levetiracetam levels fall markedly. If a switch is now undertaken, check levels each trimester.
7. Seizure safety: sleep, hydration, avoiding triggers; plan for delivery in a unit with neonatal resuscitation.
8. Vitamin K: valproate is not an enzyme inducer, so the classic neonatal vitamin K recommendation applies mainly to enzyme-inducing drugs (carbamazepine, phenytoin, primidone); follow local policy but do not present it as a substitute for risk reduction.
9. Postpartum: review the regimen before discharge and discuss breastfeeding - valproate, levetiracetam and lamotrigine are all compatible with breastfeeding.